Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. 2023;8(10):879–907.

WHO. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. July 18, 2022. https://www.who.int/publications/i/item/9789240053779. Accessed 3 Aug 2022.

Tu T, Budzinska MA, Shackel NA, Urban S. HBV DNA integration: molecular mechanisms and clinical implications. Viruses. 2017;9(4).

The expert consensus on clinical cure (functional cure) of chronic hepatitis B. J Clin Hepatobil Dis. 2019, 35(08):1693–1701.

Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691–700.

Article  PubMed  Google Scholar 

Yi S, Ren G, Zhu Y, Cong Q. Correlation analysis of hepatic steatosis and hepatitis B virus: a cross-sectional study. Virol J. 2024;21(1):22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mak LY, Hui RW, Fung J, Liu F, Wong DK, Cheung KS, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73(4):800–6.

Article  CAS  PubMed  Google Scholar 

Zhang RN, Pan Q, Zhang Z, Cao HX, Shen F, Fan JG. Saturated Fatty Acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic Fatty liver disease by toll-like receptor 4-mediated innate immune response. Hepat Mon. 2015;15(5): e27909.

Article  PubMed  PubMed Central  Google Scholar 

Du X, Shi X, Han M, Gao X, Wang C, Jiang C, et al. SCD1 inhibits HBV replication by regulating autophagy under high lipid conditions. Virus Genes. 2023;59(6):801–16.

Article  CAS  PubMed  Google Scholar 

Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int. 2014;34(Suppl 1):97–107.

Article  CAS  PubMed  Google Scholar 

Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int. 2009;3(Suppl 1):5–15.

Article  PubMed  PubMed Central  Google Scholar 

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403.

Chinese Medical Association Hepatology Branch, Chinese Medical Association Infectious Disease Branch. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). J Pract Liver Dis. 2023, 26(3):1–22

Jiangao F, Xiaoyuan X, Yuemin N, Lai W, Jidong J, Hui Z, et al. Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024). J Pract Liver Dis. 2024;27(04):494–510.

Google Scholar 

Rui F, Garcia E, Hu X, Ni W, Xue Q, Xu Y, et al. Antiviral therapy response in patients with chronic hepatitis B and fatty liver: a systematic review and meta-analysis. J Viral Hepat. 2024;31(7):372–82.

Article  CAS  PubMed  Google Scholar 

Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010;52(4):1251–7.

Article  CAS  PubMed  Google Scholar 

Ning Q, Wu D, Wang GQ, Ren H, Gao ZL, Hu P, et al. Roadmap to functional cure of chronic hepatitis B: an expert consensus. J Viral Hepat. 2019;26(10):1146–55.

Article  PubMed  Google Scholar 

Liu N, Liu B, Zhang L, Li H, Chen Z, Luo A, et al. Recovery of circulating CD56(dim) NK cells and the balance of Th17/Treg after nucleoside analog therapy in patients with chronic hepatitis B and low levels of HBsAg. Int Immunopharmacol. 2018;62:59–66.

Article  CAS  PubMed  Google Scholar 

Pang X, Zhang L, Liu N, Liu B, Chen Z, Li H, et al. Combination of pegylated interferon-alpha and nucleos(t)ide analogue treatment enhances the activity of natural killer cells in nucleos(t)ide analogue experienced chronic hepatitis B patients. Clin Exp Immunol. 2020;202(1):80–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jeng WJ, Chang ML, Liaw YF. Off-therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg-negative patients. J Viral Hepat. 2019;26(8):1019–26.

Article  CAS  PubMed  Google Scholar 

Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63(8):1325–32.

Article  CAS  PubMed  Google Scholar 

Chinese Society of Infectious DiseaseChinese Society of Hepatology. Chinese Medical Association The expert consensus on clinical cure (functional cure) of chronic hepatitis B. J Clin Hepatobil Dis. 2019;35(08):1693–701.

Google Scholar 

Xie D, Zhao H, Lu J, He F, Liu W, Yu W, et al. High uric acid induces liver fat accumulation via ROS/JNK/AP-1 signaling. Am J Physiol Endocrinol Metab. 2021;320(6):E1032–43.

Article  CAS  PubMed  Google Scholar 

Bacaksız F, Gökcan H, Akdoğan M, Gökçe DT, Arı D, Gökbulut V, et al. Role of hepatosteatosis in HBsAg seroconversion in HBeAg-negative chronic hepatitis B patients. Int J Clin Pract. 2021;75(12): e14899.

Article  PubMed  Google Scholar 

Mao X, Cheung KS, Peng C, Mak LY, Cheng HM, Fung J, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: a systematic review and meta-analysis. Hepatology. 2023;77(5):1735–45.

Article  PubMed  Google Scholar 

Huang SC, Su TH, Tseng TC, Chen CL, Hsu SJ, Liu CH, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion. Clin Gastroenterol Hepatol. 2024;22(3):581-90 e6.

Article  CAS  PubMed  Google Scholar 

Liu Q, Mu M, Chen H, Zhang G, Yang Y, Chu J, et al. Hepatocyte steatosis inhibits hepatitis B virus secretion via induction of endoplasmic reticulum stress. Mol Cell Biochem. 2022;477(11):2481–91.

Article  CAS  PubMed  Google Scholar 

Zhang J, Lin S, Jiang D, Li M, Chen Y, Li J, et al. Chronic hepatitis B and non-alcoholic fatty liver disease: conspirators or competitors? Liver Int. 2020;40(3):496–508.

Article  PubMed  Google Scholar 

Ma XJ, Tian DY, Xu D, Yang DF, Zhu HF, Liang ZH, et al. Uric acid enhances T cell immune responses to hepatitis B surface antigen-pulsed-dendritic cells in mice. World J Gastroenterol. 2007;13(7):1060–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Kleef LA, Choi HSJ, Brouwer WP, Hansen BE, Patel K, de Man RA, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep. 2021;3(5): 100350.

Article  PubMed  PubMed Central  Google Scholar 

Zhang M, Chen S, Wu X, Zhou J, Wang T, Liu H, et al. Persistent steatosis correlates with decreased fibrosis regression during anti-HBV treatment in patients with chronic HBV infection. J Med Virol. 2023;95(10): e29156.

Article  CAS  PubMed  Google Scholar 

Hui RWH, Seto WK, Cheung KS, Mak LY, Liu KSH, Fung J, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study. J Viral Hepat. 2018;25(1):97–104.

Article  CAS  PubMed  Google Scholar 

Kim HS, Kim JS, Kim JM, Han JW, Lee SK, Nam H, et al. Differential HBV replicative markers and covalently closed circular DNA transcription in immune-active chronic hepatitis B with and without HBeAg. Liver Int. 2024;44(10):2753–62.

Article  CAS  PubMed  Google Scholar 

Aggarwal A, Odorizzi PM, Brodbeck J, van Buuren N, Moon C, Chang S, et al. Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells. JHEP Rep. 2023;5(4): 100664.

Article  PubMed  Google Scholar 

Song K, Zeng D, Zheng Y, Zhang H, Weng Z, Zhou Y, et al. A simple-to-use score system for predicting HBsAg clearance to peginterferon alfa-2b in nucleoside analogs-experienced chronic hepatitis B patients. Front Med (Lausanne). 2023;10:1243202.

Article  PubMed  Google Scholar 

Hu C, Song Y, Tang C, Li M, Liu J, Liu J, et al. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: a real-world experience. Clin Ther. 2021;43(3):572-81 e3.

Article  CAS  PubMed